Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02033083
Other study ID # laminariavsdilapan
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 2013
Est. completion date February 2016

Study information

Verified date June 2021
Source Planned Parenthood of Greater New York
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective: To study the difference in dilation and evacuation (D&E) procedure time following overnight cervical preparation with laminaria or Dilapan-S™. The investigators hypothesize procedure time will be less with Dilapan-S™. Secondary objectives: To compare the use of laminaria and Dilapan-S™ for differences in: (1) initial cervical dilation before D&E; (2) need for mechanical dilation to accomplish D&E and ease of dilation if required; (3) number of osmotic dilators placed; (4) ability to complete the D&E procedure without further cervical preparation; (5) complications; (6) pain and other side effects; (7) patient acceptability; and (8) provider acceptability.


Description:

One hundred eighty women were randomized evenly across treatment arms, stratified by gestational age groups of 18 0/7-20 6/7 (n= 91) and 21 0/7-24 0/7 (n=87). The analytic sample N=173 (laminaria=86, Dilapan=87); 2 cases were removed for post-randomization exclusion and 5 for missing data on one or more outcome variables. Demographic information and results for the primary outcome of procedure time are reported below in tabular form in the results section.


Recruitment information / eligibility

Status Completed
Enrollment 180
Est. completion date February 2016
Est. primary completion date February 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age and older - Seeking pregnancy termination from 18 0/7 to 24 0/7 weeks of gestation - Eligible for pregnancy termination at Planned Parenthood of New York City - Able to give informed consent - English speaking Exclusion Criteria: - • Active bleeding or hemodynamically unstable at enrollment - Signs of chorioamnionitis or clinical infection at enrollment - Signs of spontaneous labor or cervical insufficiency at enrollment - Spontaneous intrauterine fetal demise - Allergy to laminaria or Dilapan-S™

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Laminaria

Dilapan-S


Locations

Country Name City State
United States Planned Parenthood of New York City New York New York

Sponsors (2)

Lead Sponsor Collaborator
Planned Parenthood of Greater New York Society of Family Planning

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary D&E Procedure Time Length of D&E procedure in minutes The primary outcome measure will be assessed on the day of the patient's D&E procedure. (day 2)
See also
  Status Clinical Trial Phase
Terminated NCT04063904 - Pilot Study of an Ambulatory Medical Abortion Service at 13-18 Weeks of Gestation in Colombia Phase 4
Completed NCT03400358 - Uterocervical Angle in the Pregnancy Termination of Multiparous Women N/A
Recruiting NCT04501809 - Second Trimester Pregnancy Termination in Women With Previous Caesarean Sections N/A
Recruiting NCT03044093 - Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion Phase 4
Enrolling by invitation NCT06078501 - MisOpRostol Effect on Second Trimester Abortion Blood Loss Phase 3
Completed NCT04181541 - Midlevel Versus Physician-provided Medical Abortion in the Second Trimester N/A
Completed NCT06164067 - The Role of Cervical Consistency Index and Uterocervical Angles in Medical Termination
Recruiting NCT06123026 - Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion Phase 4
Terminated NCT03714880 - Cervical Preparation With Mifepristone Prior to Osmotic Dilators Phase 2
Completed NCT03407521 - Misoprosotol and Isosorbide Mononitrate for Induction of Second Trimester Abortion Phase 4